The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer.
NLR
PLR
RAS mutation
circulating tumor DNA
neutrophil elastase
pancreatic ductal adenocarcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Mar 2021
10 Mar 2021
Historique:
received:
17
02
2021
revised:
04
03
2021
accepted:
05
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly inflammatory microenvironment and liquid biopsy has emerged as a promising tool for the noninvasive analysis of this tumor. In this study, plasma was obtained from 58 metastatic PDAC patients, and neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), circulating cell-free DNA (cfDNA) concentration, and circulating RAS mutation were determined. We found that NLR was significantly associated with both overall survival (OS) and progression-free survival. Remarkably, NLR was an independent risk factor for poor OS. Moreover, NLR and PLR positively correlated, and combination of both inflammatory markers significantly improved the prognostic stratification of metastatic PDAC patients. NLR also showed a positive correlation with cfDNA levels and RAS mutant allelic fraction (MAF). Besides, we found that neutrophil activation contributed to cfDNA content in the plasma of metastatic PDAC patients. Finally, a multi-parameter prognosis model was designed by combining NLR, PLR, cfDNA levels, RAS mutation, RAS MAF, and CA19-9, which performs as a promising tool to predict the prognosis of metastatic PDAC patients. In conclusion, our study supports the idea that the use of systemic inflammatory markers along with circulating tumor-specific markers may constitute a valuable tool for the clinical management of metastatic PDAC patients.
Identifiants
pubmed: 33802006
pii: cancers13061210
doi: 10.3390/cancers13061210
pmc: PMC7998484
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00349
Références
Gut Liver. 2018 May 15;12(3):342-352
pubmed: 29409306
Nat Rev Cancer. 2011 Feb;11(2):123-34
pubmed: 21258396
Pancreatology. 2015 Mar-Apr;15(2):145-50
pubmed: 25641673
Cells. 2019 Jul 13;8(7):
pubmed: 31337010
Ann Surg Oncol. 2015 Feb;22(2):670-6
pubmed: 25155401
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33022971
Cancer Res. 2012 Aug 15;72(16):3919-27
pubmed: 22751466
J Clin Invest. 2013 Jul 1;:
pubmed: 23863628
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229669
Front Immunol. 2019 Jul 31;10:1805
pubmed: 31417569
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
Gastroenterology. 2019 Jan;156(1):108-118.e4
pubmed: 30240661
Mamm Genome. 2016 Aug;27(7-8):358-66
pubmed: 27068925
Vet Pathol. 2020 Jan;57(1):6-23
pubmed: 31342866
Sci Rep. 2020 Oct 30;10(1):18758
pubmed: 33127996
Oncotarget. 2017 Sep 27;8(51):88835-88844
pubmed: 29179480
Oncotarget. 2017 Dec 14;8(70):115230-115243
pubmed: 29383155
Gastroenterol Res Pract. 2018 Jun 7;2018:9745601
pubmed: 29977290
Cancer Discov. 2015 Jan;5(1):52-63
pubmed: 25361845
Int J Mol Sci. 2017 Mar 29;18(4):
pubmed: 28353661
Sci Rep. 2017 Apr 9;7(1):753
pubmed: 28392554
Chin Clin Oncol. 2019 Apr;8(2):19
pubmed: 31070039
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Eur J Cancer. 2018 Jan;88:1-9
pubmed: 29175734
Clin Cancer Res. 2016 Jun 15;22(12):3067-77
pubmed: 26847055
Platelets. 2018 Sep;29(6):569-573
pubmed: 29584534
Oncoimmunology. 2019 Jun 11;8(9):e1605822
pubmed: 31428515
J Transl Med. 2018 Nov 6;16(1):300
pubmed: 30400802
Cancers (Basel). 2020 Jul 01;12(7):
pubmed: 32630266
World J Gastroenterol. 2015 Mar 7;21(9):2807-15
pubmed: 25759553
Cancer Res. 2018 Jan 1;78(1):7-14
pubmed: 29263151
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Sci Rep. 2019 Dec 23;9(1):19673
pubmed: 31873162
Nat Commun. 2020 Oct 28;11(1):5439
pubmed: 33116132
Biomarkers. 2010 Sep;15(6):516-22
pubmed: 20602543
Onco Targets Ther. 2018 Apr 05;11:1899-1908
pubmed: 29670365
Semin Cell Dev Biol. 2016 Oct;58:127-35
pubmed: 27297136
Oncogene. 2006 Mar 30;25(14):2105-12
pubmed: 16288213
Biochem Biophys Res Commun. 2018 Jun 18;501(1):313-319
pubmed: 29738769
Oncologist. 2015 Apr;20(4):e8-9
pubmed: 25777349
FEBS J. 2018 Dec;285(23):4316-4342
pubmed: 29851227
Lancet Oncol. 2015 Aug;16(8):937-48
pubmed: 26184520
Cancer Biol Ther. 2019;20(8):1057-1067
pubmed: 30990132
Clin Chim Acta. 2018 Apr;479:181-189
pubmed: 29407690
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593